NR5A2 and type 1 diabetes mellitus: We previously demonstrated that the pharmacological activation of the nuclear receptor LRH-1/NR5A2 using a small chemical agonist (BL001) could therapeutically impede the progression of hyperglycemia in 2 mouse models of T1D (NOD and RIP-B7.1) without long-term adverse effects, validating the benefits of targeting this nuclear receptor (11).